Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04441788
Other study ID # ION-827359-CS2
Secondary ID 2020-000210-15
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 22, 2020
Est. completion date August 9, 2021

Study information

Verified date November 2022
Source Ionis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.


Description:

This was a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of ION-827359 in up to 180 participants. The participants were randomized to receive oral inhalation of either ION-827359 or placebo for up to 13 weeks. At the end of 13 weeks, participants entered a 10-week post-treatment evaluation period.


Recruitment information / eligibility

Status Terminated
Enrollment 60
Est. completion date August 9, 2021
Est. primary completion date April 27, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria 1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements 2. Males or females. Aged 40-70 inclusive at the time of informed consent 3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or postmenopausal 4. BMI < 35.0 kg/m^2 5. Participants with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) 1. Ability to perform acceptable and reproducible spirometry 2. Post-bronchodilator (4 puffs of albuterol) spirometry at Screening demonstrating the following: i. FEV1/ forced vital capacity (FVC) ratio of < 0.70 ii. FEV1 = 50% and = 90% of predicted normal 6. Clinically stable COPD in the 4 weeks prior to Screening (Visit 1) 7. Current and former smokers with smoking history of = 20 pack years 8. Meet SGRQ definition of CB 9. CAT score = 10 Exclusion Criteria 1. Clinically significant abnormalities in medical history (e.g., previous acute coronary syndrome within 6 months of screening, congestive heart failure, major surgery within 3 months of Screening) or physical examination 2. Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a subject unsuitable for inclusion 1. Urine protein/creatinine (P/C) ratio = 0.3 mg/mg. In the event of P/C ratio above this threshold eligibility may be confirmed by a quantitative total urine protein measurement of < 300 mg/24 hr 2. Positive test (including trace) for blood on urinalysis. In the event of a positive test eligibility may be confirmed with urine microscopy showing = 5 red blood cells per high power field 3. alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, alkaline phosphatase (ALP), serum creatinine, blood urea nitrogen (BUN) > 1.5 × upper limit of normal (ULN) 4. Platelet count < LLN 5. Serum potassium > 5.2 mmol/L 6. Estimated GFR < 60 mL/min (as determined by the Cockcroft-Gault Equation for creatinine clearance) 7. A positive PCR test for SARS-CoV-2 at any time prior to randomization 3. Any active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to first day Study Drug product is administered to the participant (Study Day 1) 4. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator 5. Clinically important pulmonary disease other than COPD 6. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA) guidelines (GINA 2011) or other accepted guidelines. Participants with a past medical history of asthma (e.g. childhood or adolescence) may be included 7. Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for a COPD exacerbation within 4 weeks prior to enrolment (Visit 1) 8. Acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 4 weeks prior to enrolment (Visit 1) 9. Long term oxygen therapy (LTOT) 10. Participants participating in, or scheduled for, an intensive (active) COPD rehabilitation program (participants who are in the maintenance phase of a rehabilitation program are eligible to take part) 11. Concomitant medication restrictions: Oral anticoagulants, oral steroids (e.g. prednisone or Medrol), theophylline, chronic azithromycin, or roflumilast 12. Have any other conditions, which, in the opinion of the Investigator would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study

Study Design


Intervention

Drug:
ION-827359
ION-827359 administered by oral inhalation
Placebo
Placebo administered by oral inhalation
ION-827359
ION-827359 administered by oral inhalation

Locations

Country Name City State
Czechia MediTrial s.r.o. Jindrichuv Hradec
Czechia Plicni ambulance Kralupy Kralupy Nad Vltavou
Czechia CEFISPIRO s.r.o. Lovosice
Czechia Plicni Ambulance Rokycany, s.r.o. Rokycany
Czechia PNEUMOLOGIE VARNSDORF s.r.o. Varnsdorf
Germany MECS Research GmbH Berlin
Germany Pneumologisches Studienzentrum Markgrafenstrasse Berlin
Germany Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH Grosshansdorf
Germany Hamburger Institut far Therapieforschung GmbH Hamburg
Germany KLB Gesundheitsforschung Lubeck GmbH Lübeck
Germany IKF Pneumologie Mainz Helix Medical Excellence Center Mainz Mainz
Germany ZMS-Zentrum fur medizinische Studien GmbH Warendorf
Hungary Csongrad Megyei Mellkasi Betegsegek Szakkorhaza Deszk
Hungary Selye Janos Korhaz, Rendelointezet Komarom
United Kingdom Queen Anne Street Medical Centre, Heart Lung Center London

Sponsors (1)

Lead Sponsor Collaborator
Ionis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

Czechia,  Germany,  Hungary,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to the Primary Time Point in Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Baseline was defined as the last non-missing measurement prior to the first study drug administration. The primary time point was defined as the average of weeks 13 and 14. FAS=Full analysis set. From Baseline up to average of Weeks 13 and 14
Secondary Change From Baseline in the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Respiratory Symptoms (E-RS) Daily Symptom Diary Total Score to the Primary Time Point The E-RS scale is a participant-reported outcome (PRO) designed to measure the symptoms of participants with chronic obstructive pulmonary disease (COPD). The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness (comprised of 5 items, score range [0-17]), cough and sputum (comprised of 3 items, score range [0-11]), and chest symptoms (comprised of 3 items, score range [0-12]). The E-RS was collected on the daily e-diary. The total score was derived by summing the 11-item scores and ranged between 0 to 40 with higher values indicating severe respiratory symptoms. The primary time point was defined as the average of weeks 13 and 14. From Baseline up to average of weeks 13 and 14
Secondary Change From Baseline in the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) to the Week 14 Time Point The CAT is an eight-item questionnaire that was completed by the participant and is designed to quantify the impact of COPD symptoms on the health status of participants. Each item is rated on a 6-point scale ranging from 0 (no impairment) to 5 (maximum impairment). The total CAT score is calculated by summing the scores of all items and ranges from 0 to 40. Higher scores indicate a severe condition (more severe impact of COPD on a participant's life). From Baseline to Week 14
Secondary Change From Baseline in St. George's Respiratory Questionnaire - COPD Specific (SGRQ-C) Total Score to the Week 14 Time Point The SGRQ is a participant completed, a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in participants with obstructive airway disease. The shorter 40-item version (SGRQ-C) which does not specify a Recall Period and has been validated specifically for COPD participants was used in this study. It consists of 40 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicated a worse outcome (more limitations) From Baseline to Week 14
Secondary Change From Baseline in Post-Bronchodilator FEV1 Post-bronchodilator FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation after administration of bronchodilator. Baseline was defined as the last non-missing measurement prior to the first study drug administration. From Baseline to end of treatment (EOT) [Up to Week 14]
Secondary Cmax: Maximum Observed Plasma Concentration for ION-827359 Days 1 and 85
Secondary Tmax: Time to Reach the Maximum Plasma Concentration for ION-827359 Days 1 and 85
Secondary AUC[0-24h]: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours for ION-827359 Days 1 and 85
Secondary Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) Based on Severity An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of medicinal (investigational) product, whether or not the AE is considered related to the medicinal (investigational) product. A TEAE is defined as any AE starting or getting worse on or after the first dose of the study drug. The severity of a TEAE was assessed by the investigator and classified into one of the following: mild, moderate, and severe. Up to Week 24
Secondary Percentage of Participants With Clinically Significant Change in Laboratory Values Laboratory parameters for serum chemistry, hematology, urinalysis, coagulation, complement, and lipids were assessed. Up to Week 24
Secondary Percentage of Participants With Clinically Significant Change in Vital Sign Parameters Vital signs included assessment of heart rate, blood pressure, respiratory rate, and temperature. Up to Week 24
Secondary Percentage of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings ECG parameters of ventricular rate, PR interval, QRS duration, QT, or QTc were assessed. Up to Week 24
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy